Cox has a follow up on IPIX B-OM top line results.
Post# of 72440
"The topline results from the phase 2 trial are now available, and they are very good. Predictably, the market didn’t understand the data, so let’s take a closer look. The market’s ignorance is your opportunity."
"It’s important to realize, however, that pharmaceutical companies have invested massively to get even modest improvements in OM duration. With no effective treatment available, the FDA is extremely likely to approve anything that delivers even marginal relief. The topline P2 data, however, shows that Innovation Pharm’s Brilacidin provides significant reductions in incidence of severe OM."